Solidseq CGP Plus (>550 Genes Panel+TMB+MSI+HRD)

What is Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) test?

Solidseq CGP Plus is a comprehensive genomic profiling (CGP) test designed to analyze over 550 cancer-related genes in a single test. In addition to gene mutation detection, Solidseq CGP Plus test also measures:

1. TMB (Tumor Mutational Burden): The total number of mutations per coding area of a tumor genome. High TMB may indicate that the patient could respond better to certain immunotherapies.
2. MSI (Microsatellite Instability): A condition where the tumor DNA has a high mutation rate due to defects in the mismatch repair system. MSI-high tumors may respond well to immunotherapy.
3. HRD Score (Homologous Recombination Deficiency): Indicates deficiencies in DNA repair mechanisms. HRD-positive tumors may benefit from targeted therapies such as PARP inhibitors.

Solidseq CGP Plus test provides a detailed molecular profile of a patient’s tumor to help guide personalized cancer treatment.

Why consider Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) test?

Solidseq comprehensive genomic profiling (CGP) Plus test can be considered for

• Precision treatment guidance: Helps identify which targeted therapies or immunotherapies may work best for the patient.
• Detection of actionable mutations: Can reveal gene alterations that can be targeted by FDA-approved or clinical trial drugs.
• Comprehensive assessment: Combines multiple key markers (gene panel, TMB, MSI, HRD) in a single test, avoiding the need for multiple separate tests.
• Prognostic value: Provides information on how aggressive a tumor might be and potential response to therapy.

Who should get tested for Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) test?

Solidseq comprehensive genomic profiling (CGP) Plus test is recommended for

• Patients with advanced or metastatic cancers where standard treatments are limited or ineffective.
• Patients being considered for targeted therapy or immunotherapy.
• Patients with cancers known to have genetic heterogeneity or complex molecular profiles.
• Patients who are candidates for clinical trials requiring detailed genomic profiling.

More Information

Other Names - Comprehensive Genomic Profiling (CGP) Plus, Tumor Genomic Panel >550 Genes, Solidseq Tumor Profiling

Genomic profiling is the comprehensive analysis of a person’s DNA (genome) to identify mutations, gene alterations, or molecular changes that may influence disease development or progression. Genomic profiling helps in diagnosing and classifying diseases, particularly cancers, by identifying:

1. Cancer Type & Subtype:
• Some mutations are characteristic of specific cancers (e.g., EGFR in lung cancer).
2. Disease Stage & Aggressiveness:
• Certain genetic markers indicate rapid growth or likelihood of metastasis.
3. Risk Assessment:
• Germline mutations (like BRCA1/2) indicate inherited risk for breast or ovarian cancer.
4. Eligibility for Clinical Trials:
• Identifies patients who may benefit from new or experimental therapies targeting specific mutations.